Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology

Vahanian, Alec; Baumgartner, Helmut; Bax, Jeroen J.; Butchart, Eric G.; Dion, Robert; Filippatos, Gerasimos; Flachskampf, Frank A.; Hall, Roger; Iung, Bernard; Kasprzak, Jarosław D.; Nataf, Patrick; Tornos, Pilar; Torracca, Lucia; Wenink, Arnold C. G.; Priori, Silvia G.; Blanc, Jean‐Jacques; Budaj, Andrzej; Camm, John; Dean, Veronica; Deckers, Jaap W.; Dickstein, Kenneth; Lekakis, John; McGregor, Keith; Metra, Marco; Morais, João; Osterspey, A.; Zamorano, José-Luis; Angelini, Aude; Antunes, Manuel J.; Fernández, Miguel Ángel García; Gohlke-Baerwolf, Christa; Habib, Gilbert; McMurray, J.; Otto, Catherine M.; Piérard, Luc; Pomar, José L.; Prendergast, Bernard; Rosenhek, Raphaël; Uva, Miguel Sousa; Tamargo, Juan

doi:10.1093/eurheartj/ehl428

Cited by 1,231 publications

(852 citation statements)

References 261 publications

Supporting

Mentioning

760

Contrasting

Unclassified

Order By: Relevance

“…The choice between CABG and PCI should be based on a careful evaluation of the anatomy of coronary lesions, expected completeness of revascularization, comorbidities, and associated significant valvular disease [141]. Data on PCI results in patients with ischaemic HF but without angina S26 are limited.…”

Section: Myocardial Revascularization In Chronicmentioning

confidence: 99%

Guidelines on myocardial revascularization

Wijns¹,

Kolh²,

Danchin³

et al. 2011

Revista Portuguesa de Cardiologia (English Edition)

237

317

View full text Add to dashboard Cite

Section: Myocardial Revascularization In Chronicmentioning

confidence: 99%

Guidelines on myocardial revascularization

Wijns¹,

Kolh²,

Danchin³

et al. 2011

Revista Portuguesa de Cardiologia (English Edition)

237

317

View full text Add to dashboard Cite

“…Lifelong anticoagulation therapy with warfarin is also recommended in all people after artificial valve replacement. 26 Warfarin, especially if taken incorrectly, can cause severe bleeding (haemorrhages). Therefore, it is necessary to ensure that people taking warfarin have ongoing monitoring of their blood coaguability.…”

Section: Care Pathwaysmentioning

confidence: 99%

The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice: systematic review and economic evaluation

Sharma

Scotland

Cruickshank

et al. 2015

Health Technol Assess

View full text Add to dashboard Cite

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 13/06/01. The protocol was agreed in June 2013. The assessment report began editorial review in December 2013 and was accepted for publication in March 2014. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Departm...

show abstract

“…Today, the different guidelines (ESC/ACC/AHA) do not recommend mitral valve surgery for patients with an ejection fraction of 30% or less and associated comorbidity (Class IIb, Level of evidence C). 11,12 The treatment of MR in such patients is a common clinical dilemma. Operative mortality has been reported between 5 and 18% with two-year survival rates of 70% and five-year survival rates of 61%.…”

Section: Follow-up Resultsmentioning

confidence: 99%

Percutaneous mitral valve repair using the edge-to-edge technique in a high-risk population

Branden

Post²,

Swaans³

et al. 2010

NHJL

View full text Add to dashboard Cite

437orIgInAl ArtIcle percutaneous mitral valve repair using the edge-to-edge technique in a high-risk population Background. Percutaneous mitral valve (MV) repair using the edge-to-edge clip technique might be an alternative for patients with significant mitral regurgitation (MR) and an unacceptably high risk for operative repair or replacement. We report the short-term safety and efficacy of this new technique in a high-risk population. Methods. All consecutive high-risk patients who underwent percutaneous MV repair with the

show abstract

Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology

Cited by 1,231 publications

References 261 publications

Guidelines on myocardial revascularization

Guidelines on myocardial revascularization

Percutaneous mitral valve repair using the edge-to-edge technique in a high-risk population

Contact Info

Product

Resources

About